Effectiveness of Switching From Upadacitinib to Tralokinumab in Patients With Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice.

ABSTRACT:

Background

Atopic dermatitis (AD) is a chronic eczematous disorder characterized by intense itchiness. Systemic therapies for AD include Janus kinase (JAK) inhibitors and various biological agents. The effects of transitioning from the JAK1 inhibitor, upadacitinib, to the anti-interleukin 13 antibody, tralokinumab, remain unclear.

Objective

This study evaluated the transition from 15 mg of upadacitinib to tralokinumab in patients with moderate-to-severe AD.

Methods

This analysis included 20 patients who switched from 15 mg of upadacitinib to tralokinumab due to an inadequate response or adverse events (AEs). We assessed the total and regional eczema area and severity index (EASI), which included assessments of the head and neck, trunk, and upper and lower limbs, along

SUBMITTER: Hagino T 

PROVIDER: S-EPMC11965876 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature